pipeline

SPOTLIGHT: Sangamo targets gene manipulation

admin — Thu, 15 May 2008 06:59:53 -0400

Forbes has highlighted the development work of Sangamo BioSciences, which has a "hefty" pipeline of drug candidates in development that use zinc-finger DNA binding proteins to manipulate genes for a Read more...

Pfizer rumored to be eyeing MediGene buyout

admin — Wed, 14 May 2008 06:59:57 -0400

Rumors are swirling that Pfizer is looking to take over the German biotech Read more...

Merck wins the 'silver' for worst news week

admin — Mon, 05 May 2008 06:59:58 -0400

WBB Securities analyst Steve Brozak has issued a symbolic "silver medal" to Merck for worst news week. In a triple whammy rarely accomplished in the drug world, Merck had two experimental Read more...

SPOTLIGHT: Wyeth R&D chief exits with kudos for success

admin — Thu, 01 May 2008 06:59:53 -0400

The blogsters at In Vivo have weighed in on the news that Wyeth R&D chief Bob Ruffolo is retiring. He may have been tough to get along with, but the blog gives Ruffolo credit for some Read more...

Innogenetics open to Solvay's $278.2M bid

admin — Fri, 25 Apr 2008 06:59:55 -0400

Solvay has made a $278.2 million (€177.6 million) takeover bid for Belgium's Innogenetics. The companies have been R&D partners since 1997, and Solvay is the company's second largest Read more...

Vernalis inks financing deal

admin — Mon, 21 Apr 2008 06:59:55 -0400

Vernalis has signed a €18.4M financing agreement with Paul Capital Healthcare for frovatriptan, Vernalis' migraine drug. In return for the cash, Paul Capital Healthcare will receive Read more...

Aileron, Heritage Pharma each raise $10M in VC

admin — Tue, 15 Apr 2008 06:59:55 -0400

Novartis Venture Funds and Apple Tree Partners have teamed up to lead a $10 million venture round for Cambridge, MA-based Aileron Therapeutics. Aileron says it will use much of the money to expand Read more...

Antisoma starts licensing spree with cancer deal

admin — Mon, 14 Apr 2008 06:59:56 -0400

Bankrolled by a $125 million licensing deal with Novartis, the UK's Antisoma has turned around and used part of its Read more...

Boehringer boasts of late-stage drug potential

admin — Tue, 08 Apr 2008 06:59:56 -0400

A new self-assessment from Boehringer Ingelheim comes with some considerable boasting about the potential for new therapies and new indications now in its pipeline. Read more...

Biopharma execs sign on to tout UK's R&D work

admin — Mon, 07 Apr 2008 06:59:56 -0400

A high-profile crew of biopharma execs are signing on to help promote the life sciences industry in the UK. Chris Brinsmead, president of AstraZeneca U.K., will chair a 12-man strategy group for UK Read more...